CD13 promotes mesenchymal stem cell-mediated regeneration of ischemic muscle by M. Mamunur Rahman et al.
ORIGINAL RESEARCH ARTICLE
published: 09 January 2014
doi: 10.3389/fphys.2013.00402
CD13 promotes mesenchymal stem cell-mediated
regeneration of ischemic muscle
M. Mamunur Rahman1, Jaganathan Subramani1,2, Mallika Ghosh1, Jiyeon K. Denninger1,
Kotaro Takeda1, Guo-Hua Fong1, Morgan E. Carlson3,4* and Linda H. Shapiro1*
1 Center for Vascular Biology, University of Connecticut Health Center, Farmington, CT, USA
2 Department of Anesthesiology, Texas Tech University Health Sciences Center, Lubbock, TX, USA
3 Center on Aging, University of Connecticut Health Center, Farmington, CT, USA
4 Drug Discovery, Genomics Institute of the Novartis Research Foundation, San Diego, CA, USA
Edited by:
Lucas Guimarães-Ferreira, Federal
University of Espirito Santo, Brazil
Reviewed by:
Brenda Schoffstall, Barry University,
USA
Atsushi Asakura, University of
Minnesota, USA
*Correspondence:
Morgan E. Carlson, Center on
Aging, University of Connecticut
Health Center, 263 Farmington Ave.,
Farmington, CT 06030, USA
e-mail: mcarlson@gnf.org;
Linda H. Shapiro, Center for Vascular
Biology, University of Connecticut
Health Center, 263 Farmington Ave.,
Farmington, CT 06030, USA
e-mail: lshapiro@neuron.uchc.edu
Mesenchymal stem cells (MSCs) are multipotent, tissue-resident cells that can facilitate
tissue regeneration and thus, show great promise as potential therapeutic agents.
Functional MSCs have been isolated and characterized from a wide array of adult tissues
and are universally identified by the shared expression of a core panel of MSCs markers.
One of these markers is the multifunctional cell surface peptidase CD13 that has been
shown to be expressed on human and murine MSCs from many tissues. To investigate
whether this universal expression indicates a functional role for CD13 in MSC biology we
isolated, expanded and characterized MSCs from bone marrow of wild type (WT) and
CD13KO mice. Characterization of these cells demonstrated that both WT and CD13KO
MSCs expressed the full complement of MSC markers (CD29, CD44, CD49e, CD105,
Sca1), showed comparable proliferation rates and were capable of differentiating toward
the adipogenic and osteogenic lineages. However, MSCs lacking CD13 were unable to
differentiate into vascular cells, consistent with our previous characterization of CD13
as an angiogenic regulator. Compared to WT MSCs, adhesion and migration on various
extracellular matrices of CD13KO MSCs were significantly impaired, which correlated with
decreased phospho-FAK levels and cytoskeletal alterations. Crosslinking human MSCs
with activating CD13 antibodies increased cell adhesion to endothelial monolayers and
induced FAK activation in a time dependent manner. In agreement with these in vitro
data, intramuscular injection of CD13KO MSCs in a model of severe ischemic limb injury
resulted in significantly poorer perfusion, decreased ambulation, increased necrosis and
impaired vascularization compared to those receiving WT MSCs. This study suggests that
CD13 regulates FAK activation to promote MSC adhesion and migration, thus, contributing
to MSC-mediated tissue repair. CD13 may present a viable target to enhance the efficacy
of mesenchymal stem cell therapies.
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INTRODUCTION
Stem cells have the amazing capacity to contribute to the
growth and healing of many different types of tissues and
hold tremendous promise as therapeutic tools in many diseases.
However, the realization of optimal stem cell therapy is critically
dependent on the successful retention of implanted cells at the
site of injury and their effective incorporation into the damaged
tissue. Mesenchymal stem cells (MSC) are a potential source of
stem cells that have been shown to be effective in a range of cellu-
lar therapies in tissue engineering and regenerative medicine, but
the biologic mechanisms underlying their function are just being
elucidated. This knowledge is clearly essential to improving and
optimizing stem cell therapies going forward.
While no single cell surface marker unequivocally identifies
MSCs from all tissues, consensus in the field has proposed three
minimal criteria to distinguish MSCs from other hematopoietic
stem cells (Dominici et al., 2006). Characteristic MSCs (1) adhere
to plastic, (2) express a characteristic pattern of cell surface
molecules, and (3) can be differentiated into chondroblasts,
adipocytes and osteoblasts in vitro. Additional cell surface mark-
ers have been identified as being expressed on MSCs, but as they
are also expressed on other cells are not always included in the
profile. CD13 is amember of this latter group and has been shown
to be expressed on embryonic and adult stem cells isolated from
numerous sources (Aust et al., 2004; Covas et al., 2005; Fan et al.,
2005; Musina et al., 2005; Trubiani et al., 2005; Seeberger et al.,
2006). However, potential functional roles for CD13 in these cells
have not been investigated.
CD13 is a type II zinc-dependent metallopeptidase (also
known as aminopeptidase N) that is found on the surface of all
myeloid cells in addition to pericytes, activated endothelial cells,
and subsets of organ-specific epithelial cells (Funk et al., 1994;
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Jamur et al., 2005; Mina-Osorio, 2008; Armulik et al., 2011). It
is a multifunctional protein with both enzyme-dependent and
independent functions that contribute to adhesion, cell migra-
tion, angiogenesis, inflammatory trafficking, adhesion, antigen
presentation, and endocytosis (Shipp and Look, 1993; Bhagwat
et al., 2003; Luan and Xu, 2007; Petrovic et al., 2007; Winnicka
et al., 2010; Ghosh et al., 2012; Pereira et al., 2013; Rahman et al.,
2013; Subramani et al., 2013).
In this study, we phenotypically and functionally character-
ized bone marrow-derived MSC from wild type and CD13KO
mice. Isolated cells of both genotypes expressed normal profiles
of characteristic stem cell markers and were capable of differ-
entiation into the adipogenic and osteogenic lineages. However,
functional analysis showed that CD13 is important for optimal
MSC adhesion, migration and vascular network formation. In
addition, FAK phosphorylation is diminished and cytoskeletal
architecture is disrupted in CD13KO MSCs. Finally, CD13KO MSC
were impaired in their ability to mediate the recovery of perfusion
in a murine model of hind limb ischemia in vivo.
MATERIALS AND METHODS
ANIMALS
Global CD13KO mice were generated at the Gene Targeting and
Transgenic Facility at the University of Connecticut Health Center
(Winnicka et al., 2010) and back-crossed for 10 generations to the
FVB strain (The Jackson Laboratory, Bar Harbor, ME). All ani-
mals were housed under specific pathogen-free conditions with
12 h light/dark cycle and controlled temperature at the University
of Connecticut Health Center animal facilities in accordance with
Institutional and Office of Laboratory Animal Welfare guidelines.
7–8 weeks old mice were used for all experiments.
BONE MARROW DERIVED MESENCHYMAL STEM CELLS ISOLATION
AND CULTURE
MSC were isolated and cultured as previously described (Peister
et al., 2004). Briefly, the femurs and tibiae were removed, cleaned,
and flushed the marrow cells from 6 to 8 weeks old WT and
CD13KO mice. Total mononuclear cells were cultured in DMEM,
with 15% FBS on plastic dishes at 37◦C in 5% humidified CO2.
After 24 h., non-adherent cells were washed off and adherent cells
were expanded. When adherent cells were confluent (defined as
passage 0), they were continuously cultured asMSCs until passage
3. All primary cell experiments used cells at passage 4–7 to avoid
both hematopoietic cells contamination and long-term culture
effects.
HUMAN BONE MARROWMESENCHYMAL STEM CELL CULTURE
Human MSCs were purchased from Thermo Scientific
(#SV30110.02) and cultured with mesenchymal stem cell
medium (MSCM) from ScienCell (#7501) that is a complete
medium designed for optimal growth of normal human MSCs
in vitro.
REVERSE TRANSCRIPTION PCR ANALYSIS
The total cellular RNA was isolated from the wild type MSCs
(WT-MSCs) and CD13KO MSCs (KO-MSCs). PCR amplifica-
tion was performed using Invitrogen Superscript III Reverse
Transcriptase and other reagents according to manufacturer’s
instructions (Invitrogen Corporation, Carlsbad, CA). For PCR,
we used primers for Sca1, CD29, CD44, CD49e, and CD105.
All of the primer sequences were determined using established
GenBank sequences. Duplicate PCR reactions were amplified
using primers designed GAPDH as a control for analysis by
agarose gel electrophoresis.
FLOW CYTOMETRIC ASSESSMENT OF CELLULAR INFILTRATION
Flow cytometric analysis was used to characterize the phenotypes
of the MSCs. Cells were lifted with trypsin/EDTA and counted.
About 1 × 105 cells (in 100μl PBS/0.5% bovine serum albu-
min/2mmol/l EDTA) were incubated with fluorescence-labeled
monoclonal antibodies against mouse CD29, CD49e, CD34,
CD45, CD11b at 4◦C for 30min. All antibodies were purchased
fromBiolegend. Flow cytometry was performed on LSRII (Becton
Dickinson) and the data analyzed with FlowJo software (Tree
Star).
ADIPOGENIC AND OSTEOGENIC DIFFERENTIATION
Passage 4 MSCs were incubated to differentiate into adipocytes
and osteoblasts in corresponding induction medium for 3 weeks
(Peister et al., 2004). For adipogenesis, the cultures were incu-
bated in DMEM that was supplemented with 15%FBS, 100U/mL
penicillin, 100μg/ml streptomycin, 12mM L-glutamine, 5μg/ml
insulin (Sigma), 50μM indomethacin (Sigma), 1 × 10−6 M dex-
amethasone, and 0.5μM 3-isobutyl-1-methylxanthine (IBMX;
Sigma). The medium was changed 2 times per week for 3 weeks.
The cells were fixed with 10% formalin for 20min at RT and
stained with 0.5% Oil Red O (Sigma) in methanol (Sigma) for
20min at RT. For osteogenesis, the cultures were then incu-
bated in DMEM that was supplemented with 15% FBS, 100U/mL
penicillin, 100μg/ml streptomycin, 12mM L-glutamine, 20mM
β-glycerol phosphate (Sigma, St Louis, MO), 50 ng/ml thyroxine
(Sigma), 1 nM dexamethasone (Sigma), and 0.5μM ascorbate 2-
phosphate (Sigma). The media was changed 2 times per week for
3 weeks. The cells were fixed with 10% formalin for 20min at RT
and stained with Alizarin Red, pH 4.1 (Sigma) for 20min at RT.
ADHESION ASSAYS
Wells of a 96-well plate (Reacti-bind™, Pierce Biotechnology)
were coated with fibronectin (10μg/ml), Matrigel (1:100 dilu-
tion), or 1% gelatin overnight at 4◦C, washed, blocked with
100μl 1% boiled BSA for 1 h at room temperature. Cells (1 ×
104 /well/150μl) were plated for 60min at 37◦C, washed three
times, and stained with 0.5% crystal violet for 30min. Plates were
washed six times with PBS, solubilized with 100μl 1% SDS solu-
tion and adhesion was quantified with a spectrophotometer at
595 nm (Mina-Osorio et al., 2008; Kim et al., 2012).
MTT PROLIFERATION ASSAY OF MSCs
Cells were plated at a density of 6000 cells/ well/ 200μl in a 96 well
plate (None and Fibronectin coated) and were incubated with
complete medium. MTT (20μl, 5mg/ml) was added to each well
at indicated time points and incubated for 3.5 h. MTT converted
in living cells was solubilized with 4mMHCl, 0.1% Nonidet P-40
(NP40) in isopropanol and absorbance measured at 595/655 nm.
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CELL MIGRATION AND INVASION ASSAYS
Cell migration and invasion assays were performed using a BD
FluoroBlok 24-multiwell insert system (BD Biosciences). The
inserts contain a fluorescence-blocking, 8-μm pore size mem-
brane. The FluoroBlok allow quantification of the number of
cells that have migrated through the pores by microscope. To
study cell migration,MSCs were suspended in serum-free DMEM
medium, and seeded on a BD Falcon FluoroBlok 24-multiwell
insert (0.25ml of cells suspension, 1 × 104 cells per top chamber).
To study cell invasion, the FluoroBlok were coated with Matrigel
(1:5 dilutions) for 2 h at 37◦C. MSCs were suspended in serum-
free DMEM medium, and seeded on coated FluoroBlok (0.25ml
of cells suspension, 1 × 105 cells per top chamber). The bot-
tom chambers contained 0.75ml of 10% FBS contained DMEM
medium. Cells were incubated in the FluoroBlok multiwell insert
system for 4 h. (migration) and for 6 h (invasion) at 37◦C in a
humidified atmosphere of 5% CO2. Carefully cut the FluoroBlok
and coverslipped on slides using Dapi Vectashield mounting
medium (Vector Laboratories, Burlingame, CA). Photographs
and of migrated cells were taken with Axiocam MRC camera
(0.63X magnification) attached to Zeiss Axioplan 2 microscope
using a 10x objectives and counted them.
ENDOTHELIAL CELL NETWORK FORMATION ASSAY
WT and CD13KO MSCs (1 × 105) were seeded on Matrigel (BD
Biosciences, Bedford, MA) coated 24 well plates with DMEM
(10% FBS). After 12 h, images were acquired at 20X magnifica-
tion (2X objective) using a Nikon T-BPA camera attached to the
Nikon Eclipse TE2000-U. The software used was SPOT version
4.1. Three individual experiments were performed. Total numbers
of branch points per well were enumerated.
WESTERN BLOTTING
Isolated primary MSCs were lysed in ice-cold buffer (1%
NP40 lysis buffer with protease and phosphatase inhibitors).
Equal amount of protein from each group were separated by
SDS-PAGE and transferred on to PVDF membrane and incu-
bated with respective primary antibodies; CD13 monoclonal
antibody for mouse CD13 (SL-13, custom made by ProMab
Biotechnologies, Inc. Richmond, CA); 452 for human CD13 (Dr.
Meenhard Herlyn, Philadelphia, PA); pFAK 397, pFAK925, and
tFAK (cell signaling); β-Actin (Sigma); followed by incubation
with horseradish peroxidase-conjugated secondary antibodies.
The antigen-antibody complexes were detected with the use of a
chemiluminescence reagent kit (Thermoscientific).
HISTOLOGY AND IMMUNOHISTOCHEMISTRY
Mouse or human MSCs were cultured on slides and fixed in 4%
paraformaldehyde solution, permeabilized with 0.2% Triton X-
100 for 10min, and blocked with 5% BSA for 1 h. Cells were
incubated with SL-13 (dilution 1/500) for mouse CD13 staining;
452mAb (dilution 1/250) for human CD13 staining; pFAK397
and pFAK925 (cell signaling) for pFAK staining overnight fol-
lowed by fluorescence secondary antibody (dilution 1/1000) for
1 h at room temperature. For F-actin staining cells were incubated
with TRITC-phalloidin (Sigma-Aldrich, 1/100 dilution) for 1 h.
overnight followed by fluorescence secondary antibody (dilution
1/1000) for 1 h at room temperature.
After completing blood flow assessments over 21 days, gastroc-
nemius muscles were dissected, fixed in 4% paraformaldehyde
for 24 h, dehydrated, embedded in paraffin, and sectioned at
7μm thickness. After deparaffinization and rehydration, anti-
gen retrieval was done with citrate buffer pH 6 and sections
blocked and incubated overnight at 4◦C with primary antibodies
followed by fluorescent secondary antibody for 1 h at room tem-
perature. The capillaries were visualized by immunofluorescent
staining with anti-CD31 (Santa Cruz Biotechnology) (dilution
1/200). Respective fluorophore-conjugated secondary antibodies
(Molecular Probes, Carlsbad, CA) (dilution 1/1000) were used.
The slides were coverslipped using Dapi Vectashield mounting
medium (Vector Laboratories, Burlingame, CA). The capillary
density is assessed relative to the number of muscle fibers. Muscle
regeneration (fibers with centrally located nuclei/total fiber #)
in the crural muscle was analyzed by haematoxylin and eosin
staining.
Tissue sections were photographed with Optronics cam-
era attached to Ziess Axioskop 2 plus microscope using the
Zeiss Achroplan 20X objective and images were captured using
MagnaFire SP 2.1B software. Fluorescence images were pho-
tographed with Axiocam MRC camera (0.63X magnification)
attached to Zeiss Axioplan 2 microscope using a 10x, 20X, 40X or
63X objectives. For fluorescence quantification all of the images
were acquired at the same exposure.
QUANTITATIVE CELL ADHESION ASSAY AND CD13 CROSS-LINKING
Monolayer adhesion assays were performed as described previ-
ously (Mina-Osorio et al., 2008). In brief, humanMSCs (1 × 105)
were labeled with calcein for 30min at 37◦C followed by treating
with activating anti-CD13 452mAb for 30min with or without,
washed and allowed to adhere to HUVEC monolayer cells for
45min, lysed and fluorescence read at 485/530 nm and expressed
as relative fluorescence unit (RFU).
For cross-linking of CD13 on human MSCs, cells were incu-
bated with control anti-CD13 452mAb in culture medium for
0, 5, 15, and 30min at 37◦C in a humidified 5% CO2 incu-
bator. Immediately after cross-linking, the reaction was stopped
by adding 5mL of cold PBS and washed once. Cells were lysed
in 1.0% NP-40 lysis buffer (20.0mM HEPES pH 7.4, 150mM
NaCl, and 1.0% NP-40) with protease inhibitor cocktail (Roche)
and phosphatase inhibitors. Lysates were cleared by centrifuga-
tion at 7000 rpm for 15min. Proteins or immunoprecipitates were
diluted with 4X sample buffer and resolved by 10% SDS-PAGE
and electrotransfered onto a polyvinylidene difluoride membrane
(Millipore, Bedford, MA) followed by probing with pFAK397
(1:1000), followed by HRP-conjugated secondary Abs (1:5000)
and detected using the ECL- kit (Thermoscientific, USA). The
blot also stripped for tFAK and β-Actin detection.
HINDLIMB ISCHEMIA MODEL AND CELL TRANSPLANTATION
All animal procedures were performed in accordance with
the guidelines approved by the Animal Care Committee of
the University of Connecticut. Surgical grade anesthesia was
induced by intraperitoneal injection of Ketamine (100mg/kg)
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and Xylazine (10mg/kg). The right femoral artery was ligated
proximal to the deep femoral artery and distal to saphenous
artery. The deep femoral artery, superficial branches and bifur-
cation of the popliteal artery were cauterized, and the femoral
artery was completely removed between the two ligatures avoid-
ing injury of the femoral vein and nerve to preclude influence
of inflammation and edema on arteriogenesis and angiogene-
sis. Postoperative analgesia was provided with buprenorphine
(0.05mg/kg). After 4 h., the injection of PBS, wild type MSC
(WT-MSC), and CD13KO MSC (KO-MSC) were performed
intramuscularly by injecting cells (2 × 106) resuspended in PBS
at three different points (20μl in each point) into the gastrocne-
mius muscles of wild type mice with a 27 g needle (Kim et al.,
2012).
LASER-DOPPLER PERFUSION IMAGING
Non-invasive measurements of superficial hindlimb perfusion
were obtained before and 0, 3, 7, 14, and 21 days after liga-
tion using a Laser Doppler perfusion imager (model LDI2-IR,
Moor Instruments, Wilmington, DE) that was modified for high
resolution and depth of penetration (2mm) with and 830 nm
wavelength infrared 2.5mW laser diode, 100μm beam diameter,
FIGURE 1 | Mesenchymal stem cell culture and characterization. (A)
Phase contrast image of BM derived MSCs at Day 0 and Day 21(Bar =
100μm). (B) CD13 expression in WT-MSCs by fluorescence immunostaining
(Bar = 20μm) and protein expression of CD13 in WT-MSC. (C) RT PCR
analysis of stem cell expression profiles. (D) Flow cytometric analysis of
MSCs. Cells were characteristically positive for CD29, CD49e and negative
for CD19, CD31, and CD34. Unstained;WT-MSC; KO-MSC–. (E) Both
WT-MSC and KO-MSC expressed transcription factor OCT3/4 (Bar = 20μm).
(F) Confluent MSCs were transferred to adipogenic and osteogenic medium
for 3 weeks. Adipocytes were detected by oil red O staining and osteoblasts
by alizarin red staining (Bar = 200μm). (G) 1 × 105 cells were seeded on
Matrigel coated 6-well plates and incubated for 12 h. cells isolated from
CD13KO mice are unable to form capillary networks and form fewer branches
(Bar = 200μm).
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and 15 kHz bandwidth. At each time point, an average of 4
measurements per animal wasmade on anesthetized (1.5% isoflu-
orane on an isothermal heating pad). To avoid the influence of
light and temperature, the results were expressed as a ratio of per-
fusion in the right (ischemic) vs. left [non-ischemic (NI)] limb
(Limbourg et al., 2009).
IN VIVO ASSESSMENT OF LIMB FUNCTION AND ISCHEMIC DAMAGE
Semi quantitative assessment of impaired use of the ischemic limb
(ambulation score) was performed using the following criterion:
3 = most severe, unable to use the foot, dragging foot; 2 = no
dragging, but no plantar flexion (ability to flex the ankle); 1 =
positive plantar flexion; and 0 = able to flex toes to grasp cage
in response to gentle traction on the tail (Stabile et al., 2003).
Semi quantitative measurement of the ischemic damage (necrosis
score) was also assessed (1 to 5 = one to five fingernails dam-
aged, 6 to 10 = one to five fingers fully damaged, 11 = total paw
damage).
QUANTIFICATION OF CELL ENGRAFTMENT IN ISCHEMIC HINDLIMBS
Cell engraftment in the ischemic hindlimb was quantified by
histological analysis. Briefly, red fluorescent dye PKH26 labeled
WT-MSC (2 × 106) and green fluorescent dye PKH67 labeled
KO-MSC (2 × 106) were injected into ischemic hindlimbs of wild
type mice. After 7 days, the ischemic hindlimbs were harvested,
and tissue sections were embedded and sectioned. Five fields from
four tissue sections were randomly selected, and the number of
labeled cells was counted in each field (Kim et al., 2012).
STATISTICAL ANALYSIS
The data were represented as mean ± s.e.m. of the indicated
number of measurements. Statistical differences between groups
were analyzed by using unpaired, two-tailed t-test or One-Way
ANOVA. Differences were considered significant at p < 0.05.
RESULTS
MESENCHYMAL STEM CELL CULTURE AND CHARACTERIZATION
To determine if CD13 contributes to the biologic function of
stem cells we isolated MSCs from the bone marrow of wild
type and CD13KO mice. Cells of both genotypes were grossly
visually similar upon isolation and throughout the experimen-
tal culture period (Figure 1A) and as expected, the CD13 pro-
tein was abundantly expressed on wild type but not CD13KO
MSCs (Figure 1B). RT-PCR and flow cytometric analyses illus-
trated that cultured cells of both genotypes expressed equiv-
alent levels of the characteristic cell surface MSC markers
(Figures 1C,D). Similarly, immunofluorescent staining for the
pluripotency marker Oct4 verified the multipotent potential of
both wild type and CD13KO MSCs (Figure 1E). Furthermore,
characterization of cultured wild type and CD13KO MSCs showed
comparable capacities to form adipocytes and osteoclasts under
conditions reported to induce adipogenic and osteogenic dif-
ferentiation (Figure 1F). Interestingly, and consistent with our
previous data implicating CD13 as a functional regulator of
angiogenesis (Pasqualini et al., 2000; Bhagwat et al., 2001, 2003;
Petrovic et al., 2007) CD13KO MSCs were incapable of forming
endothelial networks (Figure 1G). These results confirmed CD13
as a MSC marker and suggest that CD13 is not necessary for the
formation of MSC in the bone marrow or their short-term sur-
vival in vitro after isolation. However, CD13 is required for MSC
to differentiate toward some but not all cell lineages.
CD13KO MESENCHYMAL STEM CELLS ARE FUNCTIONALLY IMPAIRED
We have previously demonstrated that CD13 functions as an
adhesion molecule regulating monocyte-endothelial interactions
(Mina-Osorio et al., 2008; Subramani et al., 2013) and is required
for endothelial cell invasion (Bhagwat et al., 2003; Petrovic et al.,
2007). To determine if CD13 functioned similarly in MSCs we
FIGURE 2 | Lack of CD13 impairs MSC adhesion, proliferation,
migration, and invasion. (A) Adhesion assay: Cells (1 × 104) were seeded
in 96 well plates coated separately with fibronectin, Matrigel, or gelatin and
allowed to adhere for 1 h at 37◦C. After PBS wash, adherent cells were
detected by MTT assay. n = 6, ∗∗P < 0.01. (B,C) Proliferation assay: Cells
(0.5 × 104) were seeded in 96 well plate and cell proliferation detected by
MTT assay at the indicated time points. n = 6, ∗P < 0.05, ∗∗P < 0.01. (D)
Migration assay: 1 × 104 cells were seeded in FluoroBlok chambers. After
4 h. incubation the cells were stained with DAPI and counted. n = 4,
∗∗P < 0.01. (E) Invasion assay: 1 × 105 cells were seeded on Matrigel (1:5
dilution) coated FluoroBlok chambers. After 6 h. incubation the cells were
counted. n = 4, ∗∗P < 0.01.
www.frontiersin.org January 2014 | Volume 4 | Article 402 | 5
Rahman et al. CD13 regulates muscle regeneration
tested wild type and CD13KO MSCs in in vitro in adhesion,
migration and invasion assays; functions that are dependent on
adhesion. Assessment of MSC adhesion to matrix proteins con-
tained in preparations of human fibronectin, Matrigel or gelatin
(Figure 2A) indicated that CD13KO MSCs are significantly less
adherent than wild type cells to all ECM proteins tested, suggest-
ing that this effect is not strictly matrix or ligand dependent and
that CD13 plays a more universal role in cell attachment. In con-
trast, proliferation rates as measured by theMTT assay are similar
over time (Figures 2B,C), although lower initial absorbance read-
ings for CD13KO cells in this assay likely reflect their overall
reduced adherence. Similar to our results in endothelial cells,
both migration and invasion of MSC toward chemotactic stimuli
were impaired (Figures 2D,E). Therefore, lack of CD13 hin-
ders MSC functions in vitro, consistent with a loss in adhesive
properties.
ADHESION-REGULATING SIGNAL TRANSDUCTION PATHWAYS ARE
ALTERED IN CD13KO MSCs
Adhesion to the extracellular matrix via adhesion molecules acti-
vates well-characterized signal transduction cascades that induce
intracellular alterations in the cytoskeleton. Staining for intra-
cellular F-actin in wild type and CD13KO MSCs with phalloidin
shows an obvious disruption of cytoskeletal integrity in the
absence of CD13 (Figure 3A). Accordingly, dramatic reductions
in phosphorylation of FAK at residues 397 and 925 and a nearly
FIGURE 3 | Mesenchymal stem cell defects in CD13KO mice are cell
intrinsic. (A) phalloidin-stained MSC cells isolated from injured muscles of
CD13KO mice showed remarkable cytoskeletal disruption compared to cells
from WT mice; Objective 40X (Bar = 100μm). (B,C) Immunofluorescent
detection of FAK phosphorylation at tyrosine residues 397 (B) and 925 (C).
Protein lysates of MSC were probed for phospho-FAK (Y397) and
phospho-FAK (Y925) with β-actin as the loading control. CD13KO MSCs
expressed lower levels of phospho-FAK protein (Bar = 20μm).
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complete absence of focal adhesions clearly indicate severely dis-
ordered adhesion processes, although total FAK protein levels
are unchanged (Figures 3B,C) suggesting CD13 regulates MSC
adhesion via FAK activation as we have previously shown in
monocytes (Subramani et al., 2013).
CD13 ACTIVATION INDUCES ADHESION AND FAK ACTIVATION IN
HUMANMSCs
We have demonstrated that activation of CD13 with a
ligand mimicking monoclonal antibody increases monocyte
adhesion to endothelial cells (Mina-Osorio et al., 2008;
Subramani et al., 2013). CD13 is also prominently expressed
in human MSCs (hMSC, Figure 4A) and may similarly
mediate MSC-endothelial adhesion. Crosslinking of hMSC
CD13 with the activating mAb 452 induces cell-cell adhesion
(Figure 4B) and FAK phosphorylation (Figure 4C), suggesting
that CD13 can function as a signal transducing adhe-
sion molecule to mediate MSC adhesion, migration and
invasion.
CD13KO MESENCHYMAL STEM CELLS ARE IMPAIRED IN ENHANCING
WOUND HEALING IN VIVO
It is well established that administration of exogenous MSCs sub-
stantially contributes to wound repair in the hind-limb ischemia
model of angiogenesis. To assess the effect of the lack of CD13
in MSC function in vivo, we removed the femoral artery and
collateral vessels from single flanks of WT mice and injected
randomized animals either with purified WT or CD13KO MSCs
or PBS control into the surgery site. Laser Dopplar imaging
of blood flow immediately following ligation clearly showed
that the ligated leg is poorly perfused (blue color) relative
to the contralateral leg (Figure 5A, day 0), but that circula-
tion is progressively re-established over a period of 3 weeks
(Figure 5A). In agreement with published studies, this revas-
cularization is significantly improved in the animals injected
with wild type MSCs compared to animals injected with vehi-
cle control (Figure 5B). In contrast, injection of CD13KO MSCs
showed a significant and prolonged delay in recovery of blood
flow over 21 days post-injury, suggesting that impaired MSC
adhesion in vitro predicts reduced MSC function in vivo in the
absence of CD13. In agreement with this result, we found reduced
ambulatory capacity (impaired limb function, Figure 5C) and
a higher degree of paw necrosis in the CD13KO animals
(Figures 5D,E).
MUSCLE GENERATION AND CAPILLARY FORMATION ARE IMPAIRED IN
MICE INJECTED WITH CD13KO MSC FOLLOWING ISCHEMIC INJURY
In vivo
Histologic analysis of muscles from animals receiving WT MSCs
at 21 days post-surgery/injection showed clear evidence of
regenerating muscle as illustrated by numerous myofibers with
centrally located nuclei (WT- Figure 6A) where vehicle con-
trols showed marked metaplasia with loss of myofibers and
decreased muscle regeneration characteristic of impaired mus-
cle recovery Figure 6A, PBS (Limbourg et al., 2009). While
CD13KO MSCs contribute to healing, muscle recovery is
noticeably reduced (Figure 6A, KO and Figure 6C). Similarly,
FIGURE 4 | CD13 activation increases monolayer adhesion and FAK
phosphorylation in human MSCs. (A) Human mesenchymal stem cells
also express CD13 by immunofluorescence (green); Objective 63X (Bar =
20μm) and immunoblot of human cell lysates. (B) Colorimetric
quantification of adhesion of human MSCs treated with the CD13 activating
mAb 452 to HUVEC monolayers. Data represents the mean ± s.e.m. n = 3
from two independent experiments (∗∗P < 0.01). (C) CD13 crosslinking
with activating mAb 452 temporally induces FAK tyrosine phosphorylation
in human MSCs.
femoral artery removal results in hypoxia that triggers a robust
angiogenic response and exogenously administered MSCs can
enhance this revascularization of injured tissue (Limbourg et al.,
2009). Immunofluorescent analysis of the vascular response to
injury indicate that the density of CD31+ endothelial cell-
lined luminal capillaries is significantly decreased in muscles
of mice receiving CD13KO MSCs (Figures 6B,D). In addition,
these structures appeared more immature with fewer charac-
teristic branches in recipients of CD13KO MSCs, confirming
our in vitro observations that CD13 is required for angio-
genesis and suggesting that CD13 promotes MSC-mediated
wound healing and revascularization in this model of ischemic
injury.
CD13 PROLONGS THE SURVIVAL AND ENGRAFTMENT OF
MESENCHYMAL STEM CELLS
The impaired muscle regeneration in recipients of CD13KO
MSCs suggests that CD13-dependent adhesion is important for
the engraftment of MSC. To estimate the relative engraftment
potential of WT and CD13KO MSCs in ischemic hindlimbs,
we directly transplanted a total of 2 × 106 differentially PKH
dye-labeled cells of each genotype into the ischemic region
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FIGURE 5 | Lack of CD13 on exogenously administered MSCs impairs
perfusion recovery in an in vivo hindlimb ischemia model. (A) Laser
Doppler flow imaging of perfusion in mice at the indicated time points.
Representative color-coded images of three groups (PBS, WT-MSC, and
KO-MSC) of mice on day 0, 3, 7, 14, and 21 after surgery and cell
transplantation assessed by laser Doppler imaging. Red indicates highest
perfusion velocity, green intermediate, and blue, lowest velocity. (B)
Cumulative results for PBS (n = 7), WT-MSC (n = 6), and KO-MSC (n = 6)
injected mice are shown graphically as ratios of blood flow in ischemic limb (I)
to that in the non-ischemic limb (NI) at each time point. Functional
assessment of ischemic muscles. Cumulative results are shown graphically
as (C) the ambulatory impairment score; (D) ischemic tissue damage score
as described in Methods. (E) Images of Non-ischemic and PBS, WT-MSC,
and KO-MSC injected ischemic paw. Black nail indicates necrosis. #P < 0.05
compare to PBS and ∗P < 0.05 compare to KO-MSC; (score assessment
criteria in Methods).
of the hindlimb injury. 7 days post-injury/transplantation,
hindlimb tissues were collected and analyzed for the number
of dye labeled cells remaining in the wound by fluorescence
microscopy (Figures 7A,B). Significantly higher numbers of
transplanted WTMSCs were detected in tissues (PKH+/nuclear-
DAPI+) than CD13KO MSCs (Figure 7C), suggesting that CD13
regulates the function of transplanted MSCs in the wound;
potentially at the level of retention, survival, or engraft-
ment potential, thus, significantly contributing to the ability
of exogenous MSCs to facilitate wound healing in ischemic
injury.
DISCUSSION
CD13 was originally identified as a marker of myeloid
leukemia and normal hematopoietic cells of the myeloid lin-
eage (Subcomittee, 1984) and was subsequently discovered to be
identical to the cell surface peptidase Aminopeptidase N (Look
et al., 1989). Further studies by our group and others have
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FIGURE 6 | Muscle regeneration and capillary formation are impaired in
mice injected with CD13KO MSC following ischemic injury. (A)
Hematoxylin and eosin (H&E) staining of gastrocnemius muscle regeneration
was confirmed by the presence of multiple, centrally located myocyte nuclei,
20X objective; Bar = 100μm. (B) Capillaries were visualized by
immunofluorescent staining with CD31 (red) and nuclei with DAPI (blue);
Objective, 40X objective; Bar = 50μm. (C) The area of the injured tissue was
compared among PBS, WT-MSC, and KO-MSC groups. A significant increase
in muscle regeneration (average) was observed in WT-MSC group compared
with PBS group at day 21. (D) The ratio of capillary density per fiber was
measured in ischemic gastrocnemius muscles. Capillary density was
significantly increased in WT-MSC compared with other groups, PBS and
KO-MSC. All data were quantified by ImagePro Plus. Values are shown as
mean ± s.e.m. (∗P < 0.05) (PBS n = 7; WT-MSC n = 6; KO-MSC n = 6).
identified numerous functional roles for this molecule in various
tissues in addition to hematopoietic cells, some of which are
enzyme-dependent [cleavage of bioactive peptides (Gros et al.,
1985), reabsorption of amino acids (McClellan and Garner,
1980)] and others that are independent of its enzymatic activity
[viral receptor (Yeager et al., 1992), adhesion molecule (Mina-
Osorio et al., 2008), endocytic mediator (Ghosh et al., 2012)
and angiogenic regulator (Bhagwat et al., 2001)]. The promi-
nent and pervasive expression of CD13 on embryonic and adult
stem cells of numerous origins (Aust et al., 2004; Covas et al.,
2005; Fan et al., 2005; Musina et al., 2005; Trubiani et al.,
2005; Seeberger et al., 2006) prompted the current investiga-
tion into possible roles for this multifunctional molecule on
MSC biology. Comparison of the in vitro and in vivo proper-
ties of bone marrow-derived mesenchymal stem cell populations
isolated from wild type and CD13KO mice showed that MSC-
expressed CD13 serves many of the functions that have been
demonstrated on other cells and that lack of CD13 on MSCs
has profound effects on the ability of exogenously administered
cells to contribute to healing of skeletal muscle following severe
ischemic injury.
Initial characterization of our global CD13KO animals showed
that unchallenged mice are healthy and fertile with essentially
normal hematopoietic profiles and physiologic myeloid functions
(Winnicka et al., 2010), similar to the normal expression pro-
files of stem cell markers and proliferation rates we observed
in freshly isolated bone marrow derived MSCs. Interestingly,
although both wild type and CD13KO MSCs express the pluripo-
tency marker Oct4 and can differentiate into cells characteristic
of the osteogenic and adipogenic lineages, MSCs lacking CD13
are unable to form vascular networks in vitro. This finding is
in agreement our previous work demonstrating that CD13 reg-
ulates angiogenesis by transducing signals important to the for-
mation of endothelial filopodia (Petrovic et al., 2007), but also
raises the intriguing possibility that CD13 may specify or deter-
mine endothelial cell fate. Consistent with this notion, we have
shown that transcription factors that mediate CD13 expression in
myeloid cells also direct the differentiation of myeloid progenitor
cells to macrophages (Hegde et al., 1998, 1999), suggesting that
CD13 may also be involved in mechanisms that program the
differentiation of specific cell lineages. Studies investigating this
interesting possibility are ongoing in our laboratory.
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FIGURE 7 | Engraftment of MSCs in vivo. Representative images of
localized PKH26 (red) labeled WT-MSCs (A) and PKH67 (green)
labeled KO-MSCs (B) at 7 days after cell injection. (C) Quantification
of engrafted MSCs. Dye positive cells was quantified. ∗P < 0.05
WT-MSC vs. KO-MSC. 5X objective, Bar = 500μm; 63X objective,
Bar = 50μm.
We have also shown that CD13 is a homotypic adhe-
sion molecule that mediates inflammatory interactions between
monocytes and endothelial cells and activation of CD13
induces signal transduction, cytoskeletal reorganization and
increased adhesion to regulate inflammatory monocyte traf-
ficking (Mina-Osorio et al., 2008; Subramani et al., 2013).
In the current study, we demonstrate that phosphorylation of
the critical focal adhesion kinase FAK and subsequent adhe-
sion of CD13KO MSCs to the extracellular matrix is also
significantly reduced. FAK phosphorylation/activation regulates
adhesion, which is fundamental to the processes of MSC sur-
vival, migration and invasion that control the ability of MSCs
to integrate, survive and contribute to healing at the site of
injury (Song et al., 2007; Hu et al., 2011; Liao et al., 2012;
Meng et al., 2013). Therefore, the reduced adhesive capacity
of MSCs resulting from the loss of CD13 profoundly affects
essential, cell intrinsic functions and likely forms the basis of
the diminished muscle regeneration seen upon CD13KO MSC
treatment.
In keeping with the defective CD13KO MSC morphogenesis
and capillary network formation, we also find that capillary den-
sity is decreased and the capillaries that are formed are immature
and poorly branched in the injuries of recipients of the CD13KO
MSCs, clearly contributing to reduced functional recovery. In
support of this notion, we have found that angiogenesis is univer-
sally impaired in CD13KO animals subjected to ischemic injury
models (Pereira et al., 2013; Rahman et al., 2013) or tumors
(Pasqualini et al., 2000; Bhagwat et al., 2003). Alternatively, the
implantedMSCs have been described as a minor source of healthy
precursor cells and wild type tissue-resident endothelial pre-
cursors are critical for neovessel formation in the wound. This
data would argue that the decrease in angiogenesis and lessened
regeneration in the CD13KO may be due to reduced survival or
retention of the MSCs in the wound, as these are a rich source
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of paracrine factors that serve to enhance repair by endogenous
cells (Williams and Hare, 2011). Indeed, studies in cardiac cell
therapy suggest that only a fraction of the donor cells actu-
ally integrate long-term, but rather function more short-term
by secreting cytokines that stimulate differentiation of tissue-
resident precursors, inhibit fibrosis, increase survival, suppress
inflammation, and promote angiogenesis (Schulman and Hare,
2012). We find that by 7 days post-injection, ischemic muscles
receiving CD13KO MSCs contained significantly fewer labeled
cells than recipients of wild type MSCs, which is consistent with
reduced survival or retention of cells lacking CD13 at the site of
injection. Interestingly, our observation that activation of CD13
on MSCs induces their adhesion suggests that activation of CD13
may be a mechanism to enhance the adhesion of implantedMSCs
to improve integration, paracrine secretion, revascularization,
muscle regeneration, and perfusion recovery.
Collectively, our results clearly indicate that CD13 plays a pro-
tective role in MSC-mediated skeletal muscle repair, which we
believe is primarily due to defects in MSC adhesion and angio-
genesis. The multifunctional nature of this molecule is consistent
with CD13’s regulation of multiple aspects of healing following
ischemic injury in the muscle and may be a potentially viable
target to improve MSC therapy.
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